Supplier News: MilliporeSigma, Bora, Sterling, Ypsomed & More
The latest from CDMOs, CMOs, and suppliers featuring MilliporeSigma, Bora Pharmaceuticals, Sterling Pharma Solutions, Ypsomed, Codis and LTS.
Biologics Manufacturing
* MilliporeSigma To Acquire the Chromatography Business of JSR Life Sciences
Formulation Development/Drug Product Manufacturing
* Bora Pharmaceuticals Adding New High-Potency Liquid-Filled Hard Capsule Line
* Codis Launches as new CDMO
* LTS To Acquire Renaissance Lakewood
Packaging
* Ypsomed Investing $248 M in US Facility
Appointments
* Sterling Pharma Solutions Appoints New CEO
Biologics Manufacturing
MilliporeSigma To Acquire the Chromatography Business of JSR Life Sciences
MilliporeSigma has signed a definitive agreement to acquire the chromatography business of JSR Life Sciences. The acquisition will expand the company’s downstream processing portfolio with advanced Protein A chromatography capabilities. The transaction is expected to close by the end of the second quarter of 2026.
Based in Belgium, the chromatography business of JSR Life Sciences has more than 50 employees and supplies chromatography products and services to pharmaceutical and biotech manufacturers worldwide.
Source: MilliporeSigma
Formulation Development/Drug Product Manufacturing
Bora Pharmaceuticals Adding New High-Potency Liquid-Filled Hard Capsule Line
Bora Pharmaceuticals has announced the addition of liquid-filled hard capsule (LFC) production capabilities at its facility in Zhunan, Taiwan.
Bora plans to have its high-potency LFC manufacturing capabilities available for customers in the first quarter of 2026. A new operational area has been designed at the facility to support the expansion, which will address the growing demand for stable delivery of sensitive compounds and complex pharmaceutical ingredients, such as oncology or potent drugs. The Zhunan facility currently supplies drug products to the US, Taiwan, and other countries throughout Asia.
Source: Bora Pharmaceuticals
Codis Launches as New CDMO
Codis has launched as a new global CDMO specializing in commercial-scale spray drying, amorphous solid dispersions, and particle-engineering technologies. Codis was formed through the integration of Particle Dynamics in the US and the Haverhill, UK, spray-drying facility previously operated by Euroapi. Codis acquired the Haverhill facility in June 2025.
With facilities in St. Louis, Missouri, Seymour, Indiana, and Haverhill, UK, Codis has over 5,000 metric tons/year of spray-drying output capacity and 300+ employees worldwide. It specializes in aqueous and solvent-based spray drying as well as amorphous solid dispersion at commercial scale with a global footprint of 40,000 square meters across the US and UK.
Source: Codis
LTS To Acquire Renaissance Lakewood
LTS Lohmann Therapie-Systeme, a pharmaceutical technology company, has acquired Renaissance Lakewood, a CDMO specializing in nasal sprays and sterile dosage forms.
With the acquisition, Renaissance facilities will become part of the worldwide operations network of LTS, along with LTS’ existing facilities in Andernach, Germany, West Caldwell, New Jersey, St. Paul, Minnesota, and Netanya, Israel.
Source: LTS Lohmann Therapie-Systeme
Packaging
Ypsomed Investing $248 M in US Facility
Ypsomed, a producer of injection systems as pens and autoinjectors, has announced plans to establish a $248-million manufacturing facility in the United States.
The company has selected Holly Springs, North Carolina, as the location and will invest around CHF 200 million ($248 million) in the first phase. From end of 2027 onwards, the new site in Holly Springs will supply products for the US market.
To accelerate its expansion, Ypsomed is buying a building with 15,000 square meters (160,000 square feet) with an option for further expansion. The company initially plans to create around 100 new jobs, with the goal of expanding the workforce to about 200 in the coming years as demand increases.
In addition, earlier this month (October 2025), Ypsomed had the topping-out ceremony for its second plant, dubbed “Schwerin 2,” in Schwerin, Germany. The company is investing more than half a billion Swiss francs ($630 million) over the coming years (as reported on October 1, 2025) in new production halls and facilities, high-bay warehouses, as well as office and technical buildings. The first construction phase of “Schwerin 2” began in January 2025, followed by a groundbreaking ceremony in March (March 2025). On an area of 37,000 square meters, production halls, a fully automated high-bay warehouse, an administration building, and a central technical facility are being built. The official inauguration and production start are planned for early 2027. In a second construction phase, another 17,000 square meters of production space will be added by 2029.
Source: Ypsomed
Appointments
Sterling Pharma Solutions Appoints New CEO
Sterling Pharma Solutions, a Dudley, UK-based CDMO of small-molecule active pharmaceutical ingredients and intermediates, has announced the appointment of Karl Rotthier, former CEO of Euroapi, as CEO, effective October 21, 2025. Rotthier succeeds Kevin Cook, who has served as CEO since 2013 and has now taken the decision to retire.
Source: Sterling Pharma Solutions
